Discovering Vismodegib in the Fight Against Skin Cancer: The First Approved Inhibitor of the Hedgehog Pathway
According to the American Cancer Society about 3 million Americans are detected with skin cancer each year and Basal Cell Carcinoma is the most common form of skin cancer found. Join Dan Sutherlin, a member of the team at Genentech who won the ACS Heroes of Chemistry award, as he presents on the discovery of vismodegib. This is the first drug to be approved by the FDA for the treatment of advanced basal cell carcinoma (BCC), giving patients with locally advanced or metastatic BCC an important treatment where there were few to no options. Clinical results with this molecule in patients with inoperable BCCs have been dramatic with many reports of tumors shrinking to where no visible signs of cancer can be detected.
*ACS Membership is required to access this recording
What You Will Learn
- What is hedgehog pathway, its biology, and general background
- How the medicinal chemistry strategy and critical modifications to earlier compounds led to this drug discovery
- What are the final drug like properties of vismodegib and a brief view into the exciting efficacy and safety this molecule has shown for some with BCC and Gorlin’s syndrome
Benefits of Membership
- ACS Webinars Archive: Every one of our 200+ past webinars available on demand
- Save Money: Members receive discounts on meetings, development courses and more!
- Access to SciFinder®: Members receive 25 complimentary SciFinder® research activities per year
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.